4.7 Article

Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients

期刊

CARDIOVASCULAR DIABETOLOGY
卷 11, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1475-2840-11-119

关键词

Type 2 diabetes; Plasma NT-proBNP; 3-D magnetic resonance imaging; White matter hyperintensities; Brain parenchymal fraction

资金

  1. Novartis
  2. Boehringer Ingelheim
  3. Merck
  4. Pfizer
  5. Sanofi-Aventis
  6. AstraZeneca

向作者/读者索取更多资源

Elevated plasma N-terminal (NT)-proBNP from the heart as well as white matter hyperintensities (WMH) in the brain predict cardiovascular (CV) mortality in the general population. The cause of poor prognosis associated with elevated P-NT-proBNP is not known but WMH precede strokes in high risk populations. We assessed the association between P-NT-proBNP and WMH or brain atrophy measured with magnetic resonance imaging (MRI) in type 2 diabetic patients, and age-matched controls. Methods and results: We measured P-NT-proBNP(ng/l) in 20 diabetic patients without prior stroke but with(n = 10) or without(n = 10) asymptomatic coronary artery disease(CAD) in order to include patients with a wide-ranging CV risk profile. All patients and 26 controls had a 3D MRI and brain volumes(ml) with WMH and brain parenchymal fraction(BPF), an indicator of brain atrophy, were determined. P-NT-proBNP was associated with WMH in linear regression analysis adjusted for CV risk factors(r = 0.94, p = 0.001) and with BPF in univariate analysis(r = 0.57, p = 0.009). Patients divided into groups of increased P-NT-proBNP levels were paralleled with increased WMH volumes(geometric mean[SD];(2.86[5.11] ml and 0.76[2.49] ml compared to patients with low P-NT-proBNP 0.20[2.28] ml, p = 0.003)) and also when adjusted for age, sex and presence of CAD (p = 0.017). The association was strengthened by CV risk factors and we did not find a common heart or brain specific driver of both P-NT-proBNP and WMH. Patients and particular patients with CAD had higher WMH, however no longer after adjustment for age and sex. Conclusion: P-NT-proBNP was associated with WMH in type 2 diabetic patients, suggesting a linkage between heart and brain disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Transplantation

HbA1c and beyond

Peter Rossing

Summary: The KDIGO guideline on Diabetes Management in Chronic Kidney Disease provides comprehensive care recommendations for patients with diabetes and CKD, focusing on glycemic control and new treatment options.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Transplantation

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study

Luis M. Ruilope, Bertram Pitt, Stefan D. Anker, Peter Rossing, Csaba P. Kovesdy, Roberto Pecoits-Filho, Pablo Pergola, Amer Joseph, Andrea Lage, Nicole Mentenich, Markus F. Scheerer, George L. Bakris

Summary: This analysis suggests that finerenone protects against kidney disease progression and cardiovascular events in patients with T2D and early or late-stage CKD.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Transplantation

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

Jennifer B. Green, Amy K. Mottl, George Bakris, Hiddo J. L. Heerspink, Johannes F. E. Mann, Janet B. McGill, Masaomi Nangaku, Peter Rossing, Charlie Scott, Alain Gay, Rajiv Agarwal

Summary: This study aims to investigate the efficacy of dual therapy with finerenone and an SGLT2i in reducing chronic kidney disease and type 2 diabetes. The results will provide important insights for improving treatment methods for kidney disease and cardiovascular risks.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Peripheral Vascular Disease

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

Rajiv Agarwal, Luis M. Ruilope, Gema Ruiz-Hurtado, Hermann Haller, Roland E. Schmieder, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Marc Lambelet, Christina Nowack, Peter Kolkhof, Amer Joseph, George L. Bakris

Summary: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, was found to reduce 24-hour, daytime, and nighttime systolic blood pressure in patients with chronic kidney disease and type 2 diabetes.

JOURNAL OF HYPERTENSION (2023)

Article Cardiac & Cardiovascular Systems

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis

Gerasimos Filippatos, Stefan D. Anker, Phyllis August, Andrew J. S. Coats, James L. Januzzi, Boris Mankovsky, Peter Rossing, Luis M. Ruilope, Bertram Pitt, Pantelis Sarafidis, John R. Teerlink, Chris J. Kapelios, Martin Gebel, Meike Brinker, Amer Joseph, Andrea Lage, George Bakris, Rajiv Agarwal

Summary: This study investigated the causes of mortality in patients with chronic kidney disease and type 2 diabetes. The findings showed that Finerenone significantly reduced the risk of all-cause and cardiovascular mortality in T2D patients across different stages of CKD, and particularly in preventing cardiovascular-related deaths and sudden cardiac death.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

Article Endocrinology & Metabolism

Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

Viktor Rotbain Curovic, Nete Tofte, Morten Lindhardt, Katarina Adamova, Stephan J. L. Bakker, Joachim Beige, Joline W. J. Beulens, Andreas L. Birkenfeld, Gemma Currie, Christian Delles, Ingo Dimos, Lidmila Francova, Marie Frimodt-Moller, Peter Girman, Ruediger Goeke, Tine W. Hansen, Tereza Havrdova, Adriaan Kooy, Gozewijnw D. Laverman, Harald Mischak, Gerjan Navis, Giel Nijpels, Marina Noutsou, Alberto Ortiz, Aneliya Parvanova, Frederik Persson, John R. Petrie, Piero L. Ruggenenti, Femke Rutters, Ivan Rychlik, Justyna Siwy, Goce Spasovski, Marijn Speeckaert, Matias Trillini, Petra Zuerbig, Heiko von der Leyen, Peter Rossing

Summary: This study examines the relationship between baseline diabetic retinopathy (DR) and the risk of developing microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes patients. The results show that the presence of DR is associated with an increased risk of developing microalbuminuria and CVEs, but not kidney function decline.

JOURNAL OF DIABETES AND ITS COMPLICATIONS (2023)

Article Endocrinology & Metabolism

The association between blood oxygen saturation and baroreflex sensitivity in adults with type 1 diabetes with and without albuminuria

Jens Christian Laursen, Christian Stevns Hansen, Marco Bordino, Marie Frimodt-Moller, Tine Willum Hansen, Luciano Bernardi, Per-Henrik Groop, Peter Rossing

Summary: This study explored the association between baroreflex sensivity and blood oxygen saturation (SpO2) in type 1 diabetes and various degrees of microvascular disease. It was found that higher baroreflex sensitivity was associated with higher SpO2 in type 1 diabetes. Compared with non-diabetic controls, type 1 diabetes patients had lower baroreflex sensitivity and lower SpO2. Therefore, hypoxia could be a therapeutic target in type 1 diabetes.

JOURNAL OF DIABETES AND ITS COMPLICATIONS (2023)

Article Medicine, General & Internal

Rationale and design of a prospective, clinical study of kidney biopsies in people with type 2 diabetes and severely increased albuminuria (the PRIMETIME 2 study)

Marie Moller, Rikke Borg, Iain Bressendorff, Lisbeth N. Fink, Eva Gravesen, Karina Haar Jensen, Torben Hansen, Dorrit Krustrup, Frederik Persson, Peter Rossing, Frederikke E. Sembach, Anne C. B. Thuesen, Ditte Hansen

Summary: Diabetic kidney disease is a severe complication of diabetes, and a kidney biopsy is the only way to accurately diagnose it. This study aims to investigate the prevalence of diabetic kidney disease in individuals with type 2 diabetes and explore potential targets for individualized treatment through in-depth molecular analysis of kidney tissue samples.

BMJ OPEN (2023)

Article Cardiac & Cardiovascular Systems

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial

Glenn M. Chertow, Ricardo Correa-Rotter, Priya Vart, Niels Jongs, John J. V. McMurray, Peter Rossing, Anna Maria Langkilde, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink

Summary: In the DAPA-CKD trial, dapagliflozin was found to reduce the risk of kidney and cardiovascular events in patients with chronic kidney disease and albuminuria. The treatment effect of dapagliflozin was consistent regardless of baseline cardiovascular medication use.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Article Endocrinology & Metabolism

Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes

Viktor Rotbain Curovic, Morten B. Houlind, Marjolein Y. A. M. Kroonen, Niels Jongs, Emilie H. Zobel, Tine W. Hansen, Juliette Tavenier, Jesper Eugen-Olsen, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Peter Rossing, Hiddo J. L. Heerspink

Summary: The effect of four different drug classes on suPAR levels in people with type 1 and type 2 diabetes was evaluated. The study showed no overall effect of the drugs on suPAR levels, but individualized treatment significantly reduced suPAR levels.

DIABETES OBESITY & METABOLISM (2023)

Letter Endocrinology & Metabolism

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Jens Christian Laursen, Viktor Rotbain Curovic, Marjolein Y. A. M. Kroonen, Niels Jongs, Emilie H. Zobel, Tine W. Hansen, Marie Frimodt-Moller, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Hiddo J. L. Heerspink, Christian Stevns Hansen, Peter Rossing

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study

Peter Rossing, Stefan D. D. Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. M. Ruilope, Liana K. K. Billings, Jennifer B. B. Green, Daisuke Koya, Ofri Mosenzon, Kevin M. M. Pantalone, Christiane Ahlers, Andrea Lage, Robert Lawatscheck, Andrea Scalise, George L. L. Bakris

Summary: This study aimed to assess the impact of finerenone on the risk of cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes, regardless of obesity. A post hoc analysis of a pooled dataset evaluated the association between waist circumference (WC), composite cardiovascular and kidney outcomes, and the effects of finerenone. The findings revealed that finerenone significantly reduced the risk of cardiovascular and kidney outcomes in the high-risk waist circumference group.

DIABETES OBESITY & METABOLISM (2023)

Article Urology & Nephrology

CKD-EPI and EKFC GFR Estimating Equations: Performance and Other Considerations for Selecting Equations for Implementation in Adults

Lesley A. Inker, Hocine Tighiouart, Ogechi M. Adingwupu, Michael G. Shlipak, Alessandro Doria, Michelle M. Estrella, Marc Froissart, Vilmundur Gudnason, Anders Grubb, Roberto Kalil, Michael Mauer, Peter Rossing, Jesse Seegmiller, Josef Coresh, Andrew S. Levey

Summary: New CKD-EPI and EKFC eGFR equations have sufficient accuracy for clinical practice. Differences in performance across subgroups reflect diversity in source populations and use of variables. Using eGFR equations with both cystatin C and creatinine can improve accuracy and uniformity of GFR estimation.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Urology & Nephrology

Discordance Between Creatinine-Based and Cystatin C-Based Estimated GFR: Interpretation According to Performance Compared to Measured GFR

Yeli Wang, Ogechi M. Adingwupu, Michael G. Shlipak, Alessandro Doria, Michelle M. Estrella, Marc Froissart, Vilmundur Gudnason, Anders Grubb, Roberto Kalil, Michael Mauer, Peter Rossing, Jesse Seegmiller, Josef Coresh, Andrew S. Levey, Lesley A. Inker

Summary: This study found that the combination of cystatin C and creatinine provides the most accurate estimates of glomerular filtration rate, especially when eGFRcr and eGFRcys are discordant.

KIDNEY MEDICINE (2023)

Review Urology & Nephrology

Can the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis?

Tobias Bomholt, Dea Kofod, Kirsten Norgaard, Peter Rossing, Bo Feldt-Rasmussen, Mads Hornum

Summary: CGM provides more detailed measurements of mean sensor glucose, glucose variability, and time in ranges, which can overcome the limitations of HbA1c in dialysis patients. It has the potential to improve glycemic control and detect hypoglycemia. However, the long-term use of CGM in the dialysis population has not been evaluated and practical burden and cost may be a limitation.

NEPHRON (2023)

暂无数据